PMGC Holdings ELAB
NASDAQ ELAB
$6.66 +0.56 (+9.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

PMGC Holdings (ELAB) Liabilities and Shareholders Equity (2022 - 2026)

PMGC Holdings (ELAB) posted Liabilities and Shareholders Equity of $26.0 million for Q1 2026, up 102.3% sequentially from $12.9 million in Q4 2025, and up 192.88% YoY from $8.9 million in Q1 2025.

PMGC Holdings (ELAB) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $26.0 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 192.88% year-over-year to $26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.2 million (up 85.02% YoY) and the FY2025 annual result came in at $12.9 million, up 43.09% from the prior year.
  • Liabilities and Shareholders Equity rose to $26.0 million in Q1 2026 per ELAB's latest filing, from $12.9 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $1.6 billion in Q3 2023 and troughed at $1.9 million in Q4 2022.
  • A 5-year average of $141.0 million and a median of $9.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity plunged 99.29% in 2024, then jumped 192.88% in 2026.
  • Over 5 years, Liabilities and Shareholders Equity stood at $1.9 million in 2022, then surged by 174.28% to $5.2 million in 2023, then jumped by 73.28% to $9.0 million in 2024, then surged by 43.09% to $12.9 million in 2025, then soared by 102.3% to $26.0 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $26.0 million, $12.9 million, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 PMGC Holdings 31.22 Mn 12.43 Mn 385,691.00 36.56 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 26.03 Mn
Dec 31, 2025 12.87 Mn
Sep 30, 2025 14.94 Mn
Jun 30, 2025 9.38 Mn
Mar 31, 2025 8.89 Mn
Dec 31, 2024 8.99 Mn
Sep 30, 2024 11.21 Mn
Jun 30, 2024 5.08 Mn
Mar 31, 2024 4.23 Mn
Dec 31, 2023 5.19 Mn
Sep 30, 2023 1.58 Bn
Dec 31, 2022 1.89 Mn